U.S. Markets open in 55 mins

Wired News – Spectrum Pharma Reported Update Data from MD Anderson’s Phase-2 Data Assessing Poziotinib in EGFR Exon 20 Mutant NSCLC Patients

Stock Monitor: Moleculin Biotech Post Earnings Reporting

LONDON, UK / ACCESSWIRE / April 12, 2018 / Active-Investors.com has just released a free research report on Spectrum Pharma, Inc. (NASDAQ: SPPI). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=SPPI as the Company's latest news hit the wire. On April 10, 2018, the Company announced that updated data from the Phase-2 clinical study evaluating poziotinib in MD Anderson's EGFR Exon 20 Mutant Non-Small Cell Lung Cancer (NSCLC) patients showed the preliminary confirmed objective response rate (ORR) and progression-free survival (PFS) benefit. Register today and get access to over 1,000 Free Research Reports by joining our site below:


Active-Investors.com is currently working on the research report for Moleculin Biotech, Inc. (NASDAQ: MBRX), which also belongs to the Healthcare sector as the Company Spectrum Pharma. Do not miss out and become a member today for free to access this upcoming report at:


Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Spectrum Pharma most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:


Spectrum to Present Complete Data from this Study Later in 2018

In the first 11 patients, the confirmed ORR was 64%. The median PFS was not reached after a median follow up of 6.5 months. In addition, the two most common adverse events observed in the study to date are skin rash and diarrhea, which are known EGFR inhibitor-related toxicities. Spectrum will present complete data from this study at a major medical meeting later in 2018.

The study at MD Anderson has far exceeded the enrollment expectations. At this point, the original cohort of 30 EGFR patients is fully enrolled and the expanded cohort of 20 patients is nearing the completion of enrollment. As enrollment in the study nears completion, MD Anderson will soon begin enrolling patients in Spectrum's ongoing multicenter Phase-2 study.

Spectrum Initiated Phase-2 Trial of Poziotinib in NSCLC Patients with exon 20 insertion mutation in EGFR or HER2

In October 2017, the Company initiated a Phase-2 trial evaluating poziotinib in NSCLC patients with an exon 20 insertion mutation in EGFR or HER2. The first patient was enrolled, and Spectrum expected to enroll patients at several leading cancer institutions in the United States. The trial was initiated following promising preliminary data from MD Anderson study.

The goal of this Phase-2 trial is to evaluate both the efficacy and safety of poziotinib in patients with NSCLC that is locally advanced or metastatic and have an exon 20 insertion mutation in either EGFR or HER2. This trial will enroll up to 87 patients with EGFR exon 20 insertion mutations and up to 87 patients with HER2 exon 20 insertion mutations in several leading cancer institutions. The study will evaluate ORR as the primary endpoint, and disease control rate (DCR), duration of response (DOR), and safety as secondary endpoints. In addition, PFS and quality of life (QoL) will be evaluated.

About Poziotinib

Poziotinib is a novel, oral, quinazoline-based tyrosine kinase inhibitor that irreversibly blocks signaling through the HER family of tyrosine-kinase receptors including HER1 (erbB1; EGFR), HER2 (erbB2), and HER4 (erbB4) as well as HER receptor mutations; this in turn can lead to inhibition of the proliferation of tumor cells that overexpress these receptors. Mutations or overexpression/amplification of EGFR family receptors have been associated with a number of different cancers, including NSCL, breast cancer, and gastric cancer.

About Non-Small-Cell Lung Carcinoma

NSCLC is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. NSCLCs are relatively insensitive to chemotherapy, compared to SCLC. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy is increasingly being used both pre-operatively and post-operatively.

About Spectrum Pharmaceuticals, Inc.

Founded in 2002 and headquartered in Henderson, Nevada, Spectrum Pharma is a commercial-stage biotechnology company with fully integrated commercial and drug development operations, and a leader in hematology/oncology. The Company's primary strategy is comprised of acquiring, developing, and commercializing a broad and diverse pipeline of late-stage clinical and commercial products.

Stock Performance Snapshot

April 11, 2018 - At Wednesday's closing bell, Spectrum Pharma's stock marginally dropped 0.67%, ending the trading session at $20.62.

Volume traded for the day: 8.58 million shares, which was above the 3-month average volume of 1.39 million shares.

Stock performance in the last month – up 8.24%; previous three-month period – up 10.92%; past twelve-month period – up 225.24%; and year-to-date - up 8.81%

After yesterday's close, Spectrum Pharma's market cap was at $2.19 billion.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors